Our preclinical facility is located in France and meets the European regulation requirements.
This full accreditation renewed for the 2nd time in 2021 demonstrates that Cynbiose is commited to uphold the gold standards for animal welfare and health & safety of our teams.
We have developed and implemented training methods and programs for an improved approach of the animals. These trainings aim to acclimate the animals to manipulations and to reduce their stress and fear through positive reinforcement techniques. They aim to improve the relationship between man and animal, especially during handling, by seeking better cooperation from the animals. These methods contribute to the improvement of animal welfare.
Our facility allows studies in biosafety level 1 to 3 to be carried out safely, rendering it particularly
well- suited for the assessment of therapies or vaccines against infectious diseases.
We have accreditations to work with GMOs as genetically modified viruses, viral vectors, vector-based genetically modified vaccines, gene therapies, cell therapies, etc… up to biosafety level 2 or even 3 under certain conditions.
Ethics is a major concern for us. All our research protocols are performed in strict accordance with EU regulations and are reviewed by an external Ethical Committee. Compliance to AAALAC guidelines is ensured by voluntary audits every 3 years.
We respect the principles of 3R testing approaches (replacement, reduction, refinement) and work on R&D projects to develop innovative assays.
The Xpansion project: unique non-clinical facility in Europe
As part of its growth and international development, Cynbiose is expanding its capacities and preclinical service offer thanks to a unique facility based in France.
This state-of-the-art facility allows us to strengthen our offer, particularly for the evaluation of drug candidates developed to fight infectious and respiratory diseases as well as GMO type products, namely gene therapies and oncolytic viruses.
Considerable attention has been paid to the architectural design to optimize biosafety, operating costs and compliance with environmental standards. A proactive approach was taken to reduce the building’s carbon footprint and aim for high environmental quality.
This project is the result of a year of reflection with expert partners and is partly funded by the Programme d’Investissements d’Avenir PIA3 for which Cynbiose was a winner late 2019.
The multi-million euro project is funded by the French government, the Auvergne-Rhône-Alpes Region, bank loans and an equity contribution.
A wide range of valuable preclinical services and facilities located in France for the worldwide biopharmaceutical industry
The facilities will be approved to handle BSL-2 to 3 as well as GMO (Class 1 to 2) studies in a number of unique models relevant to the study of infectious diseases and gene therapies.
Cynbiose will make available its new capabilities, know-how and expertise to perform preclinical studies for the global international biotech and pharmaceutical community in line with a quality controlled environment (GLP).
Where do we stand?
Construction is progressing actively, with delivery scheduled Q3 2022. Then, a period of validation and qualification of the infrastructure and equipment will start.
Moving into the offices is scheduled for October 2022 and the operational launch of the facilities is planned for the Q2 2023.
Follow the progress of the works on Linkedin.
The Xpansion project in videos
Episode 1 : The origins.
Episode 2 : A unique state-of-the-art facility.
Cynbiose’s CEO, Hugues Contamin, and our prime contractor, Pino Ciuffa, discuss the issues and challenges of our future facility. A long-term collaboration with several experts was necessary to best meet the various technical and technological challenges of the Xpansion project.
Episode 3 : A new era!
Take a look back at the groundbreaking ceremony and the progress of the construction in January 2022.
Episode 4: Meet our team and visit the site.
Episode 5: A new step forward!